GlobeNewswire

CytomX Therapeutics to Present at Upcoming November Investor Conferences
02/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will [...]
Alfasigma Announces New Linerixibat Data Across PBC and Liver Disease to be Presented at AASLD’s The Liver Meeting 2026
02/11/2026
Five presentations will highlight new analyses of linerixibat in cholestatic pruritus associated with primary biliary cholangitis, including an oral presentation and four posters from the Phase 3 GLISTEN study and real- [...]
Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data
02/11/2026
WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
02/11/2026
Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY ® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI ® 3Q 2026 net product [...]
Vireo Growth to Report Third Quarter 2026 Financial Results on November 10, 2026
02/11/2026
MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced that the Company will host a conference call on Tuesday, November 10, 2026, at 8:00 [...]
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026
02/11/2026
Company to Host Conference Call at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of [...]
Conavi Medical Completes First U.S. Commercial Placement and Clinical Cases with its OCTIV™ Hybrid Imaging System to Guide Coronary Interventions
02/11/2026
Dr. Megha Prasad and fellow physicians at NewYork-Presbyterian and Columbia complete first clinical cases with Conavi’s next-generation FDA-cleared hybrid IVUS–OCT imaging system Company introduces OCTIV™, powered by [...]
Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
02/11/2026
Commercial launch follows successful pilot, with customers reporting improved clinical decision-making and greater confidence in care decisions SUNNYVALE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq [...]
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
02/11/2026
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assessed basal cell [...]
Spectral Medical Inc. Announces Closing of First Tranche of $14.0 Million Convertible Note Private Placement, Conversion of US$4.5 Million of Maturing Convertible Notes and Repayment of US$4.5 Million of Maturing Convertible Notes
02/11/2026
TORONTO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“ Spectral ” or the “ Company ”) (TSX: EDT), a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic [...]
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
02/11/2026
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that [...]
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement
02/11/2026
BOSTON and SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
02/11/2026
WELLESLEY HILLS, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that [...]
Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation
02/11/2026
Former McKinsey associate partner and Aliaxis strategy leader to lead AI initiatives and pursue partnerships to advance pipeline programs BERKELEY HEIGHTS, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals [...]
Hinge Bio to Present Latest Results of HB2198, a Novel B-Cell Depleting Agent for Treating Autoimmune Disease, at ACR Convergence 2026
02/11/2026
Early clinical data and additional preclinical data of HB2198 will be presented at the American College of Rheumatology (ACR) Convergence 2026 REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a [...]
Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
02/11/2026
Trial met its dual primary endpoints for (1) statistically significant reduction (p=0.0168) in microglial activation as measured by TSPO PET imaging in patients treated with 50 ug nasal foralumab as compared to placebo [...]
Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome
02/11/2026
Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione Telethon Ramat Gan, Israel, Nov. [...]
Beeline Medicines Initiates First Trial in Lupus Pivotal Development Program with Global Phase 2/3 DISCOVERY Trial of Afimetoran in Cutaneous Lupus Erythematosus (CLE)
02/11/2026
– Afimetoran, an investigational oral, once-daily, equipotent TLR7/8 inhibitor, targets a central driver of lupus biology with the potential to address both cutaneous and systemic disease – – Global, randomized, double- [...]
Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026
02/11/2026
BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum